NEW YORK (GenomeWeb News) – Exiqon today reported that its first-quarter revenues fell 13 percent year over year on weak sales in North America.

The Denmark-based genomics tools and molecular diagnostics developer reported total revenues of DKK 24 million ($4.2 million) for the three months ended March 31, compared to DKK 27.6 million for the first quarter of 2011. It said that organic sales growth for research products was 25 percent in Europe, offset by a 33 percent decline in North America, where it said that it is implementing a new sales strategy.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.